Lumavita is uniquely positioned as the only specialty pharmaceutical company dedicated to the global development and marketing of new drugs to combat infections for women's health.
Latest News
27.08.2009
Lumavita AG announces Marketing Authorisation for Pentamycin in Switzerland
Read More
Read More
18.06.2009
Lumavita AG announces new funding - €4m raised in Series A follow-on
Read More
Read More
24.03.2009
Lumavita AG announces receipt of Preliminary Approval for Marketing Authorisation of pentamycin in Switzerland for the
treatment of three types of vaginitis
Read More
Read More